TSC22 domain family member 2Genealiases: TILZ4a · TILZ4b · TILZ4c
Q-omics provides the consensus-scored TSC22D2 profile across patient tissues and cancer cell-line models. TSC22D2 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, TSC22D2 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, TSC22D2 protein abundance shows 21,587 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRP, and HNSC as cancer lineages where TSC22D2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TSC22D2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TSC22D2 survival associations across molecular data types. TSC22D2 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TSC22D2 RNA expression–survival associations across cancer types. High TSC22D2 expression shows unfavorable associations in KIRP, ACC, MESO, HNSC, PAAD and BLCA. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KIRP as the clearest survival context for TSC22D2 RNA expression.
This table summarizes TSC22D2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for TSC22D2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TSC22D2 shows lower tumor expression in THCA, KIRC and UCEC and higher tumor expression in HNSC, LUAD and ESCA. The HNSC box plot shows higher TSC22D2 RNA expression in tumor versus normal tissue (log2 FC = +0.917, t-test p < 0.001).
This table shows molecular features associated with TSC22D2 in patient tissues and cancer cell lines. In patient samples, TSC22D2 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, TSC22D2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Myeloma.
